Page last updated: 2024-09-03

elacridar and Mouth Neoplasms

elacridar has been researched along with Mouth Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kim, HS; Lee, BM; Park, Y; Son, JY; Yoon, S	1

Other Studies

1 other study(ies) available for elacridar and Mouth Neoplasms

Article	Year
Highly Eribulin-resistant KBV20C Oral Cancer Cells Can Be Sensitized by Co-treatment with the Third-generation P-Glycoprotein Inhibitor, Elacridar, at a Low Dose. Anticancer research, 2017, Volume: 37, Issue:8 Topics: Acridines; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Furans; Humans; Ketones; Mouth Neoplasms; Tetrahydroisoquinolines	2017

Article

Year

Highly Eribulin-resistant KBV20C Oral Cancer Cells Can Be Sensitized by Co-treatment with the Third-generation P-Glycoprotein Inhibitor, Elacridar, at a Low Dose.

Anticancer research, 2017, Volume: 37, Issue:8

Topics: Acridines; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Furans; Humans; Ketones; Mouth Neoplasms; Tetrahydroisoquinolines

2017